{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T23:05:18Z","timestamp":1761865518924,"version":"build-2065373602"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T00:00:00Z","timestamp":1750636800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T00:00:00Z","timestamp":1750636800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Z Gerontol Geriat"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1007\/s00391-025-02454-0","type":"journal-article","created":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T13:54:40Z","timestamp":1750686880000},"page":"324-335","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Androgendeprivative Therapie des Prostatakarzinoms aus geriatrischer Sicht","Androgen deprivation therapy of prostate cancer from a\u00a0geriatric perspective"],"prefix":"10.1007","volume":"58","author":[{"given":"A.","family":"Wiedemann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Becher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Manseck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Stein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Fr\u00f6hner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Fiebig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Piotrowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Kirschner-Hermanns","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Bannowsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Wirz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Salem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T. H.","family":"Kuru","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,6,23]]},"reference":[{"key":"2454_CR1","unstructured":"https:\/\/de.statista.com\/statistik\/daten\/studie\/1423163\/umfrage\/10-jahres-praevalenz-von-prostatakrebs-bei-maennern-ab-65-jahren"},{"key":"2454_CR2","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1001\/jama.280.11.975","volume":"280","author":"PC Albertsen","year":"1998","unstructured":"Albertsen\u00a0PC, Hanley\u00a0JA, Gleason\u00a0DF, Barry\u00a0MJ (1998) Competing risk analysis of men aged 55 to 74\u00a0years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA 280:975\u2013980","journal-title":"JAMA"},{"key":"2454_CR3","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s12894-018-0384-x","volume":"18","author":"AS Zakaria","year":"2018","unstructured":"Zakaria\u00a0AS, Dragomir\u00a0A, Brimo\u00a0F, Kassouf\u00a0W, Tanguay\u00a0S, Aprikian\u00a0A (2018) Changes in the outcome of prostate biopsies after preventive task force recommendation against prostate-specific antigen screening. BMC Urol 18:69","journal-title":"BMC Urol"},{"key":"2454_CR4","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1200\/JCO.2010.31.2330","volume":"29","author":"PC Albertsen","year":"2011","unstructured":"Albertsen\u00a0PC, Moore\u00a0DF, Shih\u00a0W, Lin\u00a0Y, Li\u00a0H, Lu-Yao\u00a0GL (2011) Impact of comorbidity on survival among men with localized prostate cancer. J\u00a0Clin Oncol 29:1335\u20131341","journal-title":"J Clin Oncol"},{"key":"2454_CR5","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1056\/NEJMoa1715546","volume":"378","author":"MR Smith","year":"2018","unstructured":"Smith\u00a0MR, Saad\u00a0F, Chowdhury\u00a0S et\u00a0al (2018) Apalutamide treatment and metastasis-free survival in prostate cancer. N\u00a0Engl J Med 378:1408\u20131418","journal-title":"N Engl J Med"},{"key":"2454_CR6","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1056\/NEJMoa1800536","volume":"378","author":"M Hussain","year":"2018","unstructured":"Hussain\u00a0M, Fizazi\u00a0K, Saad\u00a0F et\u00a0al (2018) Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer. N\u00a0Engl J Med 378:2465\u20132474","journal-title":"N Engl J Med"},{"key":"2454_CR7","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1056\/NEJMoa1405095","volume":"371","author":"TM Beer","year":"2014","unstructured":"Beer\u00a0TM, Armstrong\u00a0AJ, Rathkopf\u00a0DE et\u00a0al (2014) Enzalutamide in metastatic prostate cancer before chemotherapy. N\u00a0Engl J Med 371:424\u2013433","journal-title":"N Engl J Med"},{"key":"2454_CR8","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1056\/NEJMoa1815671","volume":"380","author":"K Fizazi","year":"2019","unstructured":"Fizazi\u00a0K, Shore\u00a0N, Tammela\u00a0TL et\u00a0al (2019) Darolutamide in nonmetastatic, castration-resistant prostate cancer. N\u00a0Engl J Med 380:1235\u20131246","journal-title":"N Engl J Med"},{"key":"2454_CR9","doi-asserted-by":"publisher","first-page":"3595","DOI":"10.1200\/JCO.23.00041","volume":"41","author":"M Hussain","year":"2023","unstructured":"Hussain\u00a0M, Tombal\u00a0B, Saad\u00a0F et\u00a0al (2023) Darolutamide plus androgen-deprivation therapy and Docetaxel in metastatic hormone-sensitive prostate cancer by disease volume and risk subgroups in the phase\u00a0III ARASENS trial. J\u00a0Clin Oncol 41:3595\u20133607","journal-title":"J Clin Oncol"},{"key":"2454_CR10","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.2217\/fon-2022-0433","volume":"18","author":"MR Smith","year":"2022","unstructured":"Smith\u00a0MR, Hussain\u00a0M, Saad\u00a0F et\u00a0al (2022) Darolutamide and survival in metastatic, hormone-sensitive prostate cancer: a\u00a0patient and caregiver perspective and plain language summary of the ARASENS trial. Future Oncol 18:2585\u20132597","journal-title":"Future Oncol"},{"key":"2454_CR11","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/S0140-6736(10)61389-X","volume":"376","author":"JS de Bono","year":"2010","unstructured":"de Bono\u00a0JS, Oudard\u00a0S, Ozguroglu\u00a0M et\u00a0al (2010) Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a\u00a0randomised open-label trial. Lancet 376:1147\u20131154","journal-title":"Lancet"},{"key":"2454_CR12","doi-asserted-by":"publisher","first-page":"91","DOI":"10.3109\/13697137.2015.1125460","volume":"19","author":"MS Hunter","year":"2016","unstructured":"Hunter\u00a0MS, Stefanopoulou\u00a0E (2016) Vasomotor symptoms in prostate cancer survivors undergoing androgen deprivation therapy. Climacteric 19:91\u201397","journal-title":"Climacteric"},{"key":"2454_CR13","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1038\/s41391-018-0036-y","volume":"21","author":"HS Ng","year":"2018","unstructured":"Ng\u00a0HS, Koczwara\u00a0B, Roder\u00a0D, Vitry\u00a0A (2018) Development of comorbidities in men with prostate cancer treated with androgen deprivation therapy: an Australian population-based cohort study. Prostate Cancer Prostatic Dis 21:403\u2013410","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"2454_CR14","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1634\/theoncologist.2011-0174","volume":"16","author":"PK Morrow","year":"2011","unstructured":"Morrow\u00a0PK, Mattair\u00a0DN, Hortobagyi\u00a0GN (2011) Hot flashes: a\u00a0review of pathophysiology and treatment modalities. Oncologist 16:1658\u20131664","journal-title":"Oncologist"},{"key":"2454_CR15","doi-asserted-by":"publisher","first-page":"2823","DOI":"10.1002\/pon.3355","volume":"22","author":"CU Eziefula","year":"2013","unstructured":"Eziefula\u00a0CU, Grunfeld\u00a0EA, Hunter\u00a0MS (2013) You know I\u2019ve joined your club... I\u2019m the hot flush boy\u2019: a\u00a0qualitative exploration of hot flushes and night sweats in men undergoing androgen deprivation therapy for prostate cancer. Psychooncology 22:2823\u20132830","journal-title":"Psychooncology"},{"key":"2454_CR16","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1186\/s13643-015-0099-y","volume":"4","author":"B Hutton","year":"2015","unstructured":"Hutton\u00a0B, Yazdi\u00a0F, Bordeleau\u00a0L et\u00a0al (2015) Comparison of physical interventions, behavioral interventions, natural health products, and pharmacologics to manage hot flashes in patients with breast or prostate cancer: protocol for a\u00a0systematic review incorporating network meta-analyses. Syst Rev 4:114","journal-title":"Syst Rev"},{"key":"2454_CR17","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1002\/pon.3794","volume":"24","author":"E Stefanopoulou","year":"2015","unstructured":"Stefanopoulou\u00a0E, Yousaf\u00a0O, Grunfeld\u00a0EA, Hunter\u00a0MS (2015) A\u00a0randomised controlled trial of a\u00a0brief cognitive behavioural intervention for men who have hot flushes following prostate cancer treatment (MANCAN). Psychooncology 24:1159\u20131166","journal-title":"Psychooncology"},{"key":"2454_CR18","first-page":"7938","volume":"22","author":"LM Hirsch","year":"2015","unstructured":"Hirsch\u00a0LM, Goldstein\u00a0LE (2015) Acupuncture for hot flashes in men treated with androgen deprivation therapy. Can J Urol 22:7938\u20137941","journal-title":"Can J Urol"},{"key":"2454_CR19","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.eururo.2004.12.003","volume":"47","author":"H Van Poppel","year":"2005","unstructured":"Van Poppel\u00a0H, Tyrrell\u00a0CJ, Haustermans\u00a0K et\u00a0al (2005) Efficacy and tolerability of radiotherapy as treatment for bicalutamide-induced gynaecomastia and breast pain in prostate cancer. Eur Urol 47:587\u2013592","journal-title":"Eur Urol"},{"key":"2454_CR20","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.eururo.2013.11.002","volume":"65","author":"A Heidenreich","year":"2014","unstructured":"Heidenreich\u00a0A, Bastian\u00a0PJ, Bellmunt\u00a0J et\u00a0al (2014) EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 65:467\u2013479","journal-title":"Eur Urol"},{"key":"2454_CR21","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.clgc.2012.03.002","volume":"10","author":"V Serretta","year":"2012","unstructured":"Serretta\u00a0V, Altieri\u00a0V, Morgia\u00a0G et\u00a0al (2012) A\u00a0randomized trial comparing tamoxifen therapy vs. tamoxifen prophylaxis in bicalutamide-induced gynecomastia. Clin Genitourin Cancer 10:174\u2013179","journal-title":"Clin Genitourin Cancer"},{"key":"2454_CR22","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1016\/S0090-4295(97)00457-3","volume":"50","author":"VR Staiman","year":"1997","unstructured":"Staiman\u00a0VR, Lowe\u00a0FC (1997) Tamoxifen for flutamide\/finasteride-induced gynecomastia. Urology 50:929\u2013933","journal-title":"Urology"},{"key":"2454_CR23","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/1741-7015-10-96","volume":"10","author":"F Kunath","year":"2012","unstructured":"Kunath\u00a0F, Keck\u00a0B, Antes\u00a0G, Wullich\u00a0B, Meerpohl\u00a0JJ (2012) Tamoxifen for the management of breast events induced by non-steroidal antiandrogens in patients with prostate cancer: a\u00a0systematic review. BMC Med 10:96","journal-title":"BMC Med"},{"key":"2454_CR24","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1080\/21681805.2019.1570328","volume":"53","author":"MH Poulsen","year":"2019","unstructured":"Poulsen\u00a0MH, Frost\u00a0M, Abrahamsen\u00a0B, Gerke\u00a0O, Walter\u00a0S, Lund\u00a0L (2019) Osteoporosis and prostate cancer; a\u00a024-month prospective observational study during androgen deprivation therapy. Scand J Urol 53:34\u201339","journal-title":"Scand J Urol"},{"key":"2454_CR25","doi-asserted-by":"publisher","first-page":"39562","DOI":"10.1038\/srep39562","volume":"7","author":"SH Kim","year":"2017","unstructured":"Kim\u00a0SH, Joung\u00a0JY, Kim\u00a0S et\u00a0al (2017) Comparison of bone mineral loss by combined androgen block agonist versus GnRH in patients with prostate cancer: A\u00a012\u00a0month-prospective observational study. Sci Rep 7:39562","journal-title":"Sci Rep"},{"key":"2454_CR26","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1111\/j.1464-410X.2011.10097.x","volume":"107","author":"ER Jefferies","year":"2011","unstructured":"Jefferies\u00a0ER, Thurairaja\u00a0R, Persad\u00a0RA, Rajani\u00a0R, Phull\u00a0JS, Bahl\u00a0A (2011) Don\u2019t think once, think twice! the cardiovascular effects of androgen deprivation therapy. BJU Int 107:1023\u20131028","journal-title":"BJU Int"},{"key":"2454_CR27","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.prnil.2018.04.002","volume":"7","author":"A Ohtaka","year":"2019","unstructured":"Ohtaka\u00a0A, Aoki\u00a0H, Nagata\u00a0M et\u00a0al (2019) Sarcopenia is a\u00a0poor prognostic factor of castration-resistant prostate cancer treated with docetaxel therapy. Prostate Int 7:9\u201314","journal-title":"Prostate Int"},{"key":"2454_CR28","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1111\/1754-9485.12124","volume":"58","author":"D Chang","year":"2014","unstructured":"Chang\u00a0D, Joseph\u00a0DJ, Ebert\u00a0MA et\u00a0al (2014) Effect of androgen deprivation therapy on muscle attenuation in men with prostate cancer. J\u00a0Med Imaging Radiat Oncol 58:223\u2013228","journal-title":"J Med Imaging Radiat Oncol"},{"key":"2454_CR29","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1186\/s12885-018-4306-9","volume":"18","author":"JK Dawson","year":"2018","unstructured":"Dawson\u00a0JK, Dorff\u00a0TB, Schroeder\u00a0TE, Lane\u00a0CJ, Gross\u00a0ME, Dieli-Conwright\u00a0CM (2018) Impact of resistance training on body composition and metabolic syndrome variables during androgen deprivation therapy for prostate cancer: a\u00a0pilot randomized controlled trial. BMC Cancer 18:368","journal-title":"BMC Cancer"},{"key":"2454_CR30","doi-asserted-by":"publisher","first-page":"e016910","DOI":"10.1136\/bmjopen-2017-016910","volume":"7","author":"JL Kiwata","year":"2017","unstructured":"Kiwata\u00a0JL, Dorff\u00a0TB, Schroeder\u00a0TE et\u00a0al (2017) A\u00a0pilot randomised controlled trial of a\u00a0periodised resistance training and protein supplementation intervention in prostate cancer survivors on androgen deprivation therapy. BMJ Open 7:e16910","journal-title":"BMJ Open"},{"key":"2454_CR31","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.acuro.2015.01.004","volume":"39","author":"JI Monzo-Gardiner","year":"2015","unstructured":"Monzo-Gardiner\u00a0JI, Herranz-Amo\u00a0F (2015) Cardiovascular mortality in patients with prostate cancer exposed to androgen deprivation therapy. Actas Urol Esp 39:518\u2013522","journal-title":"Actas Urol Esp"},{"key":"2454_CR32","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1177\/1756287215617872","volume":"8","author":"P Zareba","year":"2016","unstructured":"Zareba\u00a0P, Duivenvoorden\u00a0W, Leong\u00a0DP, Pinthus\u00a0JH (2016) Androgen deprivation therapy and cardiovascular disease: what is the linking mechanism? Ther Adv Urol 8:118\u2013129","journal-title":"Ther Adv Urol"},{"key":"2454_CR33","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1002\/jcph.1332","volume":"59","author":"HH Kao","year":"2019","unstructured":"Kao\u00a0HH, Kao\u00a0LT, Li\u00a0IH et\u00a0al (2019) Androgen deprivation therapy use increases the risk of heart failure in patients with prostate cancer: a\u00a0population-based cohort study. J\u00a0Clin Pharmacol 59:335\u2013343","journal-title":"J Clin Pharmacol"},{"key":"2454_CR34","doi-asserted-by":"crossref","unstructured":"Margel D, Peer A, Ber Y et\u00a0al (2019) Cardiovascular morbidity in a\u00a0randomized trial comparing GnRH agonist and GnRH antagonist among patients with advanced prostate cancer and preexisting cardiovascular disease. J\u00a0Urol: 101097JU0000000000000384","DOI":"10.1097\/JU.0000000000000384"},{"key":"2454_CR35","doi-asserted-by":"publisher","first-page":"695170","DOI":"10.3389\/fendo.2021.695170","volume":"12","author":"A Sciarra","year":"2021","unstructured":"Sciarra\u00a0A, Busetto\u00a0GM, Salciccia\u00a0S et\u00a0al (2021) Does exist a\u00a0differential impact of Degarelix versus LHRH agonists on cardiovascular safety? Evidences from randomized and real-world studies. Front Endocrinol 12:695170","journal-title":"Front Endocrinol"},{"key":"2454_CR36","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1007\/s00120-015-0013-1","volume":"55","author":"AS Merseburger","year":"2016","unstructured":"Merseburger\u00a0AS, Sedding\u00a0D, Huter\u00a0K (2016) Cardiovascular risk patients under androgen deprivation therapy: Lower risk with GnRH antagonists compared to LHRH agonists? Urologe\u00a0A 55:218\u2013225","journal-title":"Urologe A"},{"key":"2454_CR37","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1097\/EDE.0000000000000678","volume":"28","author":"BM Hicks","year":"2017","unstructured":"Hicks\u00a0BM, Klil-Drori\u00a0AJ, Yin\u00a0H, Campeau\u00a0L, Azoulay\u00a0L (2017) Androgen deprivation therapy and the risk of anemia in men with prostate cancer. Epidemiology 28:712\u2013718","journal-title":"Epidemiology"},{"key":"2454_CR38","first-page":"3877","volume":"10","author":"D Dai","year":"2018","unstructured":"Dai\u00a0D, Han\u00a0S, Li\u00a0L et\u00a0al (2018) Anemia is associated with poor outcomes of metastatic castration-resistant prostate cancer, a\u00a0systematic review and meta-analysis. Am J Transl Res 10:3877\u20133886","journal-title":"Am J Transl Res"},{"key":"2454_CR39","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1007\/s12672-018-0335-8","volume":"9","author":"Z Chen","year":"2018","unstructured":"Chen\u00a0Z, Deng\u00a0J, Yan\u00a0Y et\u00a0al (2018) Risk analysis of prostate cancer treatments in promoting metabolic syndrome development and the influence of increased metabolic syndrome on prostate cancer therapeutic outcome. Horm Cancer 9:278\u2013287","journal-title":"Horm Cancer"},{"key":"2454_CR40","unstructured":"Tully KH, Nguyen DD, Herzog P et\u00a0al (2019) Risk of dementia and depression in young and middle-aged men presenting with nonmetastatic prostate cancer treated with androgen deprivation therapy. Eur Urol Oncol"},{"key":"2454_CR41","doi-asserted-by":"crossref","unstructured":"Ceylan Y, Gunlusoy B, Koskderelioglu A, Gedizlioglu M, Degirmenci T (2019) The depressive effects of androgen deprivation therapy in locally advanced or metastatic prostate cancer: a\u00a0comparative study. Aging Male: 1\u20137","DOI":"10.1080\/13685538.2019.1586869"},{"key":"2454_CR42","doi-asserted-by":"publisher","first-page":"593","DOI":"10.4143\/crt.2018.119","volume":"51","author":"BS Tae","year":"2019","unstructured":"Tae\u00a0BS, Jeon\u00a0BJ, Shin\u00a0SH, Choi\u00a0H, Bae\u00a0JH, Park\u00a0JY (2019) Correlation of androgen deprivation therapy with cognitive dysfunction in patients with prostate cancer: a\u00a0nationwide population-based study using the national health insurance service database. Cancer Res Treat 51:593\u2013602","journal-title":"Cancer Res Treat"},{"key":"2454_CR43","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1016\/j.urolonc.2012.07.003","volume":"31","author":"LM Wu","year":"2013","unstructured":"Wu\u00a0LM, Diefenbach\u00a0MA, Gordon\u00a0WA, Cantor\u00a0JB, Cherrier\u00a0MM (2013) Cognitive problems in patients on androgen deprivation therapy: a\u00a0qualitative pilot study. Urol Oncol 31:1533\u20131538","journal-title":"Urol Oncol"},{"key":"2454_CR44","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.socscimed.2016.03.016","volume":"156","author":"LM Wu","year":"2016","unstructured":"Wu\u00a0LM, Tanenbaum\u00a0ML, Dijkers\u00a0MP et\u00a0al (2016) Cognitive and neurobehavioral symptoms in patients with non-metastatic prostate cancer treated with androgen deprivation therapy or observation: A\u00a0mixed methods study. Soc Sci Med 156:80\u201389","journal-title":"Soc Sci Med"},{"key":"2454_CR45","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1111\/ajco.12347","volume":"11","author":"J Yang","year":"2015","unstructured":"Yang\u00a0J, Zhong\u00a0F, Qiu\u00a0J, Wang\u00a0K (2015) Cognitive function in Chinese prostate cancer patients on androgen-deprivation therapy: a\u00a0cross-sectional study. Asia Pac J Clin Oncol 11:277\u2013281","journal-title":"Asia Pac J Clin Oncol"},{"key":"2454_CR46","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1001\/jamaoncol.2016.3662","volume":"3","author":"KT Nead","year":"2017","unstructured":"Nead\u00a0KT, Gaskin\u00a0G, Chester\u00a0C, Swisher-McClure\u00a0S, Leeper\u00a0NJ, Shah\u00a0NH (2017) Association between androgen deprivation therapy and risk of dementia. JAMA Oncol 3:49\u201355","journal-title":"JAMA Oncol"},{"key":"2454_CR47","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1186\/1471-2407-12-371","volume":"12","author":"HH Chao","year":"2012","unstructured":"Chao\u00a0HH, Uchio\u00a0E, Zhang\u00a0S et\u00a0al (2012) Effects of androgen deprivation on brain function in prostate cancer patients\u2014a\u00a0prospective observational cohort analysis. BMC Cancer 12:371","journal-title":"BMC Cancer"},{"key":"2454_CR48","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1038\/s41391-018-0037-x","volume":"21","author":"MM Cherrier","year":"2018","unstructured":"Cherrier\u00a0MM, Cross\u00a0DJ, Higano\u00a0CS, Minoshima\u00a0S (2018) Changes in cerebral metabolic activity in men undergoing androgen deprivation therapy for non-metastatic prostate cancer. Prostate Cancer Prostatic Dis 21:394\u2013402","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"2454_CR49","doi-asserted-by":"publisher","first-page":"12007","DOI":"10.1038\/srep12007","volume":"5","author":"AM Moilanen","year":"2015","unstructured":"Moilanen\u00a0AM, Riikonen\u00a0R, Oksala\u00a0R et\u00a0al (2015) Discovery of ODM-201, a\u00a0new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies. Sci Rep 5:12007","journal-title":"Sci Rep"},{"key":"2454_CR50","doi-asserted-by":"publisher","first-page":"e333","DOI":"10.1093\/ehjci\/jeac106","volume":"23","author":"AR Lyon","year":"2022","unstructured":"Lyon\u00a0AR, Lopez-Fernandez\u00a0T, Couch\u00a0LS et\u00a0al (2022) 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J Cardiovasc Imaging 23:e333\u2013e465","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"5","key":"2454_CR51","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/j.euo.2024.06.001","volume":"7","author":"LM Cordes","year":"2024","unstructured":"Cordes LM, Karzai F, Madan RA (2024) Enzalutamide Monotherapy in the EMBARK trial should be practice-changing and existing data suggest how to mitigate toxicity. Eur Urol Oncol 7(5):971\u2013972. https:\/\/doi.org\/10.1016\/j.euo.2024.06.001. Epub 2024 Jun 29. PMID: 38945782","journal-title":"Eur Urol"}],"container-title":["Zeitschrift f\u00fcr Gerontologie und Geriatrie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00391-025-02454-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00391-025-02454-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00391-025-02454-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T13:03:38Z","timestamp":1751979818000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00391-025-02454-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,23]]},"references-count":51,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["2454"],"URL":"https:\/\/doi.org\/10.1007\/s00391-025-02454-0","relation":{},"ISSN":["0948-6704","1435-1269"],"issn-type":[{"type":"print","value":"0948-6704"},{"type":"electronic","value":"1435-1269"}],"subject":[],"published":{"date-parts":[[2025,6,23]]},"assertion":[{"value":"20 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"Gem\u00e4\u00df den Richtlinien des Springer Medizin Verlags werden Autoren und Wissenschaftliche Leitung im Rahmen der Manuskripterstellung und Manuskriptfreigabe aufgefordert, eine vollst\u00e4ndige Erkl\u00e4rung zu ihren finanziellen und nichtfinanziellen Interessen abzugeben.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"A.\u00a0Bannowsky: A.\u00a0Finanzielle Interessen: A.\u00a0Bannowsky gibt an, dass kein finanzieller Interessenkonflikt besteht. \u2013\u00a0B.\u00a0Nichtfinanzielle Interessen: Angestellter Chefarzt, Klinik f\u00fcr Urologie, Klinik Diepholz | Mitgliedschaften: DGU, ESSM, DGSMTW, EAU, Dt. Kontinenzgesellschaft, Vereinigung norddeutscher Urologen. K.\u00a0Becher: A.\u00a0Finanzielle Interessen: \u00dcbernahme der Reise- und \u00dcbernachtungskosten sowie Referentenhonorare von den Firmen Ferring, Dr. Pfleger, Aristo, Omega, Astellas.\u00a0\u2013 Beratungst\u00e4tigkeit bei den Firmen Ferring, Omega und Pfizer. \u2013\u00a0B.\u00a0Nichtfinanzielle Interessen: Angesteller Chefarzt der Klinik Wartenberg Professor Dr. Selmair GmbH & Co. KG | Mitgliedschaften: Arbeitskreis Benignes Prostatasyndrom der Deutschen Gesellschaft f\u00fcr Urologie | Deutschen Gesellschaft f\u00fcr Geriatrie (Leitlinienbeauftragter). C.\u00a0Fiebig: A.\u00a0Finanzielle Interessen: Finanzielle Forschungsf\u00f6rderung durch die Deutsche Forschungsgemeinschaft (DFG) im Rahmen der DFG-Nachwuchsakademie.\u00a0\u2013 Reisekostenerstattung durch: Ipsen Pharma GmbH, Honorar als Referent durch: Merck Healthcare Germany GmbH. \u2013\u00a0B.\u00a0Nichtfinanzielle Interessen: Angestellter Arzt am Uniklinikum Erlangen, Urologische und Kinderurologische Klinik | Mitgliedschaften: Deutsche Gesellschaft f\u00fcr Urologie (DGU), European Association of Urology (EAU), Soci\u00e9t\u00e9 Internationale d\u2019Urologie (SIU). M.\u00a0Fr\u00f6hner: A.\u00a0Finanzielle Interessen: M.\u00a0Fr\u00f6hner gibt an, dass kein finanzieller Interessenkonflikt besteht.\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: Chefarzt, Klinik f\u00fcr Urologie, Zeisigwaldkliniken Bethanien Chemnitz. R.\u00a0Kirschner-Hermanns: A.\u00a0Finanzielle Interessen: Seit 2025 CEO und Gr\u00fcnder der MEC\/ABC GmbH. R.\u00a0Kirschner-Hermanns best\u00e4tigt, dass diese Firma nicht an den f\u00fcr die im Beitrag erw\u00e4hnten Zulassungsstudien beteiligt war. \u2013\u00a0B.\u00a0Nichtfinanzielle Interessen: Angestellte Urologin und wissenschaftliche Leitung Neuro-Urologie, Johanniter Neurologisches Rehabilitationszentrum Godesh\u00f6he, Bonn. 2012\u20132023 angestellte Urologin, Sektionsleitung Neuro-Urologie, Klinik und Poliklinik f\u00fcr Urologie, Universit\u00e4tsklinikum Bonn. Heute noch affiliiert. Pr\u00e4sidentin und Gr\u00fcnderin des F\u00f6rdervereins zur Kontinenzforschung und Kontinenzaufkl\u00e4rung e.\u202fV. Stellvertretende Vorsitzende der Arbeitsgemeinschaft der Deutschen Gesellschaft der Urologie: Geriatrische Urologie. Gr\u00fcndungsmitglied der internationalen Gesellschaft f\u00fcr Neuro-Urologie (INUS). Deutsche Gesellschaft f\u00fcr Neurorehabilitation (DGNR). European Society for Sexual Medicine (ESSM). Deutsche medizinische Gesellschaft f\u00fcr Paraplegie (DMGP). International Spinal Cord Society (ISCOS). Arbeitsgemeinschaft f\u00fcr Urogyn\u00e4kologie und plastische Beckenbodenrekonstruktion e.\u202fV. (AGUB). International Consultation on Incontinence Modular Questionnaire (ICIQ). ICIQ Advisory Board, Arbeitsgruppe: Development of an incontinence questionnaire for the cognitively impaired persons with incontinence. International Consultation on Incontinence Research Society (ICIR). International Continence Society (ICS). American Urological Society (AUA). European Association of Urology (EAU). International Consultation on Incontinence (ICI). T.H.\u00a0Kuru: A.\u00a0Finanzielle Interessen: Vortragshonorare oder Kostenerstattung als passiv Teilnehmende: Dr. Pfleger, Janssen-Cilag, Pierre Fabre Pharma.\u00a0\u2013 Bezahlte Beratungsleistungen, interne Schulungsvortr\u00e4ge, Gehaltsbezug o.\u202f\u00e4.: Ambu. \u2013\u00a0B.\u00a0Nichtfinanzielle Interessen: Urologe in BAG, K\u00f6ln | Mitgliedschaften: EAU, BDU. A.\u00a0Manseck: A.\u00a0Finanzielle Interessen: Vortragshonorare oder Kostenerstattung als passiv Teilnehmende: Boston Scientific, Intercom Dresden, ConTag Dresden, DGU.\u00a0\u2013 Bezahlte Beratungsleistungen, interne Schulungsvortr\u00e4ge, Gehaltsbezug o.\u202f\u00e4.: BLAEK, Landesdirektion Sachsen, OnkoZert. \u2013\u00a0B.\u00a0Nichtfinanzielle Interessen: Angestellter Arzt f\u00fcr Urologe Klinikum Ingolstadt | Mitgliedschaften: Arbeitskreis \u201eGeriatrische Urologie\u201c der Deutschen Gesellschaft f\u00fcr Urologie, Schriftf\u00fchrer; Arbeitskreis \u201erobotische Chirurgie\u201c der Deutschen Gesellschaft f\u00fcr Urologie, Kassenwart; Deutsche Gesellschaft f\u00fcr Urologie; Berufsverband der Deutschen f\u00fcr Urologie; Deutsche Kontinenz Gesellschaft; Beratungsstelle der Deutschen Kontinenz Gesellschaft; Bayerische Urologenvereinigung, 1.\u00a0Vorsitzender bzw. Vizepr\u00e4sident, bzw. Generalsekret\u00e4r; Deutsche Gesellschaft f\u00fcr Roboter-Assistierte Urologie (Kassenpr\u00fcfer); European Association of Urology; American Assosciation of Urology; Beirat F\u00f6rderverein Krebskranker der Region Ingolstadt e.\u202fV.; Fachexperte OnkoZert; Ausschuss Zertifikatserteilung f\u00fcr Uro-Onkologische Zentren; Zertifizierungskommission (Prostata) der DKG; Zertifizierungskommission (Harnblase) der DKG; Zertifizierungskommission (Niere) der DKG. A.\u00a0Piotrowski: A.\u00a0Finanzielle Interessen: Forschungsf\u00f6rderung zur pers\u00f6nlichen Verf\u00fcgung: Dr. Pfleger Arzneimittel: Studient\u00e4tigkeit, Bayer: Advisory board.\u00a0\u2013 Fortbildungskosten: Intuitive | Pr\u00e4sentation: Olympus. \u2013\u00a0B.\u00a0Nichtfinanzielle Interessen: Chefarzt, Klinik f\u00fcr Urologie und Kinderurologie, Klinikum Bad Hersfeld. J.\u00a0Salem: A.\u00a0Finanzielle Interessen: J.\u00a0Salem gibt an, dass kein finanzieller Interessenkonflikt besteht.\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: Niedergelassener Urologe | Mitgliedschaften: Berufsverband der deutschen Urologen, Deutsche Gesellschaft f\u00fcr Urologie. J.\u00a0Stein: A.\u00a0Finanzielle Interessen: Patente, Gesch\u00e4ftsanteile, Aktien o.\u202f\u00e4. an einer im Medizinbereich aktiven Firma: Biontech, Eli Lilly, Novo Nordisk, Bristol Myers Squibb |. \u2013\u00a0B.\u00a0Nichtfinanzielle Interessen: Chefarzt der Urologischen Klinik, Klinikum Grossburgwedel (Klinikum Region Hannover) | Mitgliedschaften: Deutsche Gesellschaft f\u00fcr Urologie, Deutsche Gesellschaft f\u00fcr Andrologie, EAU, Berufsverband der Urologen, Verband der leitenden Krankenhaus\u00e4rzte, Norddeutsche Urologenvereinigung, Uro-Onkologischer Arbeitskreis Niedersachsen, Deutsche Krebsgesellschaft, Vorstand Arbeitskreis Uro-Geriatrie der DGU, Arbeitskreis der leitenden Krankenhaus\u00e4rzte der DGU | Fachexperte OnkoZert zur Zertifizierung Onkologischer Zentren. A.\u00a0Wiedemann: A.\u00a0Finanzielle Interessen: Forschungsf\u00f6rderung zur pers\u00f6nlichen Verf\u00fcgung: Paul-Kuth-Stiftung, Dr. Robert-Pfleger-Stiftung, AMS Deutschland, Boston Scientific, Omega Pharma |.\u00a0\u2013 Vortragshonorare oder Kostenerstattung als passiv Teilnehmende: Allergan, Apogepha, Aristo, Astellas Pharma, Bayer, Berlin-Chemie, Boston-Scientific, bene Arzneimittel, Jansen, Karo Pharma, Lilly Deutschland, Meda, Medac, Medice, MIP Pharma, Dr. Pfleger, Pfizer Pharma, Pierre Pharma, Das Fortbildungskolleg, med-update, uro-update |. \u2013\u00a0Acticore, Astellas, Bayer, bene Arzneimittel, Dr. Pfleger, Pfizer, Pierre Fabre, MEC-Abc, Merck, Novartis |.\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: Angestellter Arzt EVK Witten gGmbH | Mitgliedschaften: Deutsche Kontinenz Gesellschaft (Vorsitz), Dt. Ges. f\u00fcr Urologie, NRW-Ges. f\u00fcr Urologie, Dt. Ges. f\u00fcr Geriatrie. S.\u00a0Wirz: A.\u00a0Finanzielle Interessen: Vortragshonorare oder Kostenerstattung als passiv Teilnehmende: Gr\u00fcnenthal, Mundipharma international, Dr. Pfleger, Cannaflos\/Digitale Health Care, Kyowa Kirin, Besins, PACE. \u2013\u00a0Bezahlte Beratungsleistungen, interne Schulungsvortr\u00e4ge, Gehaltsbezug o.\u202f\u00e4.: Mundipharma international, Dr. Pfleger, Cannaflos\/Digitale Health Care, Kyowa Kirin, Stada, Hexal.\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: CA, GFO-Kliniken Bonn; Betriebsst\u00e4tte Cura Bad Honnef | Sprecher Arbeitskreis Tumorschmerz der Deutschen Schmerzgesellschaft; Past Chair Cancer Special Interest Group IASP | Mitgliedschaften: Deutsche Schmerzgesellschaft; IASP; DGAI; BDA; BVSD; DGS; Sert\u00fcrner Gesellschaft.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Autoren"}},{"value":"Die vollst\u00e4ndige Erkl\u00e4rung zum Interessenkonflikt der Wissenschaftlichen Leitung finden Sie am Kurs der zertifizierten Fortbildung auf .","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Wissenschaftliche Leitung"}},{"value":"erkl\u00e4rt, dass f\u00fcr die Publikation dieser CME-Fortbildung keine Sponsorengelder an den Verlag flie\u00dfen.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}}]}}